Results 311 to 320 of about 414,727 (380)

Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun   +19 more
wiley   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens   +14 more
wiley   +1 more source

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza   +26 more
wiley   +1 more source

Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The clinical effectiveness of tezacaftor‐ivacaftor in children with cystic fibrosis (cwCF) varies; some patients respond while others do not or have adverse effects. The pharmacokinetics (PK) of tezacaftor‐ivacaftor are inadequately published, especially in children.
Steffie E. M. Vonk   +7 more
wiley   +1 more source

Single‐component cationic polyethylenimine thermogel for sustained and localized gene delivery to combat multi‐drug resistant cancer

open access: yesBMEMat, EarlyView.
A cationic thermogelling copolymer employing branched PEI‐25 kDa as the sole hydrophilic segment can be facilely complexed with plasmid by physical mixing in the sol phase. Spontaneous gelation is achieved via self‐assembly after injection due to physiological temperature. Sustained and localized release of plasmid from the cationic PEI‐thermogel leads
Qianyu Lin   +11 more
wiley   +1 more source

N‐1 semi‐continuous transient perfusion in shake flask for ultra‐high density seeding of CHO cell cultures in benchtop bioreactors

open access: yesBiotechnology Progress, EarlyView.
Abstract One strategy to enhance the production of biological therapeutics is using transient perfusion in the preculture (N‐1 stage) to seed the production culture (N stage) at ultra‐high cell densities (>10 x 106 viable cells/mL). This very high seeding density improves cell culture performance by shortening the timeline and/or achieving higher final
Lucas Lemire   +5 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

open access: yesCancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy